1-2 of 2
Tressa Hood, MSc
Close
Sort by
Journal Articles

Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Jayakumar Vadakekolathu, PhD, Mark D. Minden, MD PhD, Tressa Hood, MSc, Sarah E. Church, PhD, Stephen Reeder, BSc, Heidi Altmann, PhD, Amy H Sullivan, BSc, Elena J Viboch, MSc, Tasleema Patel, Narmin Ibrahimova, Sarah E. Warren, PhD, Andrea Arruda, Marc Schmitz, MD, Yan Liang, PhD, Alessandra Cesano, MD PhD, A. Graham Pockley, PhD, Peter Valk, PhD, Bob Löwenberg, MD PhD, Martin Bornhäuser, MD, Sarah K. Tasian, MD, Michael P. Rettig, PhD, Jan K Davidson-Moncada, MD PhD, John F. DiPersio, MD PhD, Sergio Rutella, MDPhDFRCPath
Journal: Blood
Blood (2019) 134 (Supplement_1): 460.
https://doi.org/10.1182/blood-2019-121870
Published: 2019
Journal Articles

Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 × CD3 Bispecific Dart ® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Sergio Rutella, MD PhD FRCPath, Sarah E. Church, PhD, Jayakumar Vadakekolathu, PhD, Elena Viboch, MSc, Amy H Sullivan, BSc, Tressa Hood, MSc, Sarah E. Warren, PhD, Alessandra Cesano, MD PhD, Ross La Motte-Mohs, PhD, John Muth, MS, Helene Lelièvre, PhD PharmD, Bob Lowenberg, MD, John F. DiPersio, MD PhD, Jan K Davidson-Moncada, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 444.
https://doi.org/10.1182/blood-2018-99-111539
Published: 2018